Acute coronary syndrome is associated with a substantial change in the platelet lipidome

Tobias Harm1, Alexander Bild1, Kristina Dittrich2

  • 1Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Straße 10, 72076 Tübingen, Germany.

Insights

Platelet lipids change significantly in coronary artery disease (CAD). Specific glycerophospholipids increase in acute coronary syndrome (ACS), promoting platelet activation and thrombus formation, impacting cardiovascular events.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Lipidomics

Background:

  • Platelets are crucial in coronary artery disease (CAD) pathophysiology.
  • Enhanced platelet activation increases cardiovascular event risk.
  • Platelet lipid profiles significantly change in CAD patients.

Purpose of the Study:

  • Investigate platelet lipidome alterations in CAD using untargeted liquid chromatography-mass spectrometry.
  • Compare lipid profiles between acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) patients.
  • Identify specific lipids involved in ACS pathophysiology and their impact on platelet function.

Main Methods:

  • Characterized the platelet lipidome in a cohort of 139 CAD patients.
  • Utilized untargeted liquid chromatography-mass spectrometry for lipid profiling.
  • Analyzed differences in lipid profiles between ACS and CCS patient groups.

Main Results:

  • Identified significant differences in platelet lipids between ACS and CCS patients.
  • Found 7 platelet glycerophospholipids significantly up-regulated and 25 down-regulated in ACS compared to CCS.
  • The prominent up-regulated lipid, PC18:0, enhanced platelet activation and thrombus formation.

Conclusions:

  • The platelet lipidome is altered in ACS, with glycerophospholipids being primarily up-regulated.
  • Medium-chain lipid alterations in platelets may contribute to ACS pathophysiology.
  • These findings highlight potential therapeutic targets for managing ACS.
Abstract

Related Concept Videos

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
95
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
180
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
111
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
774
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
54
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.8K